The US National Institutes of Health has awarded a $600,000 two-year contract for the development, by Colorado-based Rocky Mountain Biosystems Inc, of a self-administered vaccination electromechanical technology (SAVE) for use with an anti-influenza therapy. The aim is to provide a needle-free and easy to use delivery system for a vaccine to be used in the event of a pandemic, probably caused by a mutation of the H5N1 strain of the avian influenza virus (Marketletters passim).
Kevin Marchitto, RMBI's chief executive, said: "we believe we can deliver vaccine protection to nearly all of the US population within days of an outbreak." He added that the SAVE technology may reduce the amount of vaccine required per patient and ensure better coverage for very young and elderly people.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
| Headless Content Management with Blaze